ReviewAdvances in therapy2015
Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy.
Review in Advances in therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.Hormones (Athens, Greece) · 2022Pooled it
- Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.Internal medicine (Tokyo, Japan) · 2020Trial
- Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis.Frontiers in pharmacology · 2025Article
- Association and Interaction between Heavy Metals and Hyperuricemia in a Taiwanese Population.Diagnostics (Basel, Switzerland) · 2023Article
- Development and internal validation of a risk model for hyperuricemia in diabetic kidney disease patients.Frontiers in public health · 2022Article
- Effect Modification of Hyperuricemia, Cardiovascular Risk, and Age on Chronic Kidney Disease in China: A Cross-Sectional Study Based on the China Health and Nutrition Survey Cohort.Frontiers in cardiovascular medicine · 2022Article
- Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.Frontiers in endocrinology · 2021Review
- Genetically Engineered Human Kidney Cells for Real-Time Cytotoxicity Testing In Vitro.Molecular biotechnology · 2020Article
- Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.Clinical and experimental nephrology · 2020Review
- Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.Clinical drug investigation · 2018Article
- Does Altered Uric Acid Metabolism Contribute to Diabetic Kidney Disease Pathophysiology?Current diabetes reports · 2018Review
- Chronic kidney disease associated with decreased bone mineral density, uric acid and metabolic syndrome.PloS one · 2018Article
- Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial.EXCLI journal · 2018Article
- Diet and enteral nutrition in patients with chronic kidney disease not on dialysis: a review focusing on fat, fiber and protein intake.Journal of nephrology · 2017Review
- Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association.Current hypertension reports · 2017Review
- Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.Journal of advanced research · 2017Review
- Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy - A review.Journal of advanced research · 2017Review
- Time to target uric acid to retard CKD progression.Clinical and experimental nephrology · 2017Review
- Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy.Reviews in endocrine & metabolic disorders · 2017Review
- Relationship between hyperuricemia and risk of coronary heart disease in a middle-aged and elderly Chinese population.The Journal of international medical research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledChronic kidney disease (CKD) is increasingly recognized as a global health problem, and new and effective strategies are needed for the management of this condition. Recently, there has been renewed interest in the relationship between serum uric acid (SUA) levels and CKD, and several recent trials have demonstrated a possible link between SUA and the development and/or progression of CKD in patients with and without diabetes. The identification of key urate transporters such as urate transporter 1 and glucose transporter 9 has provided not only insights into the pathophysiology of hyperuricemia, but also possible links to other processes, such as glucose homeostasis. The renewed interest in the role of SUA in CKD has coincided with the development of sodium glucose co-transporter 2 inhibitors for the treatment of diabetes. In addition to improving glycemic control, these agents, acting via the kidneys in an insulin-independent manner, have also been shown to reduce SUA levels and potentially improve some measures of renal function. This review will discuss the role of uric acid in CKD treatment, and how SUA-lowering therapies may prevent or delay the progression of CKD.
fundingJanssen Scientific Affairs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.